糖皮质激素致乙型肝炎病毒再激活——皮肤科亟须重视的问题

doi:10.3760/cma.j.issn.0412-4030.2019.02.016

Abstract

Abstract: 【Abstract】 There is a high incidence of hepatitis B virus （HBV） infection in China, and dermatologists often encounter patients with skin diseases complicated by HBV infection in clinic. With the widespread use of systemic glucocorticoids in dermatology, HBV reactivation has become a constant problem to face in the treatment process. Attention should be given to risk factors of HBV reactivation, including HBV DNA replication, positive hepatitis B surface antigens （HBsAg） and positive hepatitis B core antibodies （HBcAb）. According to HBV serological markers, risk stratification of HBV reactivation induced by glucocorticoids needs to be grasped, and treatment measures should be taken timely to prevent HBV reactivation. In this way, liver function impairment induced by HBV reactivation during the course of glucocorticoid therapy may be avoided to the greatest extent, which is of great benefit to clinical work.

Key words: Glucocorticoids, Hepatitis B virus, Hepatitis B, Virus activation

Song Xiuzu, Hua You. Hepatitis B virus reactivation induced by glucocorticoids: an important issue requiring urgent attention in dermatology[J].Chinese Journal of Dermatology, 2019, 52(2): 124-127.

References ［24］

［1］	Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression［J］. Hepatology, 2015,61（3）:823⁃833. doi: 10.1002/hep.27604.
［2］	Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression ⁃ prevention is better than cure［J］. World J Hepatol, 2015,7（7）:954⁃967. doi: 10.4254/wjh.v7.i7.954.
［3］	Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy［J］. Nat Rev Gastroenterol Hepatol, 2014,11（4）:209⁃219. doi: 10.1038/nrgastro.2013.216.
［4］	Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus （HBV） reactivation in cancer patients undergoing cytotoxic chemotherapy［J］. Br J Cancer, 2004,90（7）:1306⁃1311. doi: 10.1038/sj.bjc.6601699.
［5］	Ferraro D, Pizzillo P, Di MV, et al. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?［J］. Liver Int, 2009,29（8）:1171⁃1177. doi: 10.1111/j.1478⁃3231.2009.02071.x.
［6］	Pérez⁃Alvarez R, Díaz⁃Lagares C, García⁃Hernández F, et al. Hepatitis B virus （HBV） reactivation in patients receiving tumor necrosis factor （TNF）⁃targeted therapy: analysis of 257 cases［J］. Medicine （Baltimore）, 2011,90（6）:359⁃371. doi: 10. 1097/MD.0b013e3182380a76.
［7］	An J, Shim JH, Kim SO, et al. Comprehensive outcomes of on⁃ and off⁃antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: a competing risks analysis［J］. J Med Virol, 2016,88（9）:1576⁃1586. doi: 10.1002/jmv.24512.
［8］	Mei B, Chen Y, Liu W, et al. mRNA of glucocorticoid receptor and serological and virological markers of chronic hepatitis B［J］. Mol Med Rep, 2015,11（3）:2215⁃2220. doi: 10. 3892/mmr.2014.2931.
［9］	喻一奇, 宣丹旦, 王佳俐, 等. 风湿性疾病合并乙型肝炎病毒感染12例不同免疫抑制治疗后病毒再激活的随访观察［J］. 中华风湿病学杂志, 2015,19（4）:261⁃266. doi: 10.3760/cma.j.issn.1007⁃7480.2015.04.011.
［10］	Kim TW, Kim MN, Kwon JW, et al. Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids［J］. Respirology, 2010,15（7）:1092⁃1097. doi: 10.1111/j.1440⁃1843.2010.01798.x.
［11］	Cheng AL, Hsiung CA, Su IJ, et al. Steroid⁃free chemotherapy decreases risk of hepatitis B virus （HBV） reactivation in HBV⁃carriers with lymphoma［J］. Hepatology, 2003,37（6）:1320⁃1328. doi: 10.1053/jhep.2003.50220.
［12］	Li X, Tian J, Wu J, et al. A comparison of a standard⁃dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study［J］. Clin Ther, 2009,31（4）:741⁃750. doi: 10.1016/j.clinthera.2009.04.011.
［13］	Law MF, Ho R, Cheung CK, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy［J］. World J Gastroenterol, 2016,22（28）:6484⁃6500. doi: 10.3748/wjg.v22.i28.6484.
［14］	Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy［J］. Gastroenterology, 2015,148（1）:215⁃219. doi: 10.1053/j.gastro.2014.10.039.
［15］	Karadag Ö, Kaşifoglu T, Özer B, et al. Viral hepatitis screening guideline before biological drug use in rheumatic patients［J］. Eur J Rheumatol, 2016,3（1）:25⁃28. doi: 10.5152/eurjrheum.2015. 150072.
［16］	Perrillo RP, Gish R, Falck⁃Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosu⁃ppressive drug therapy［J］. Gastroenterology, 2015,148（1）:221⁃244.e3. doi: 10.1053/j.gastro.2014.10.038.
［17］	Ohishi W, Chayama K. Prevention of hepatitis B virus reacti⁃vation in immunosuppressive therapy or chemotherapy［J］. Clin Exp Nephrol, 2011,15（5）:634⁃640. doi: 10.1007/s10157⁃011⁃0464⁃7.
［18］	Yoo JJ, Cho EJ, Cho YY, et al. Efficacy of antiviral prophylaxis in HBsAg⁃negative, anti⁃HBc positive patients undergoing hematopoietic stem cell transplantation［J］. Liver Int, 2015,35（12）:2530⁃2536. doi: 10.1111/liv.12882.
［19］	Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab⁃containing chemotherapy for lymphoma: a prospective study［J］. J Clin Oncol, 2014,32（33）:3736⁃3743. doi: 10.1200/JCO.2014.56.7081.
［20］	Buti M, Manzano ML, Morillas RM, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti⁃HBc⁃positive patients with rituximab⁃based regimens to treat hematologic malignancies: The Preblin study［J］. PLoS One, 2017,12（9）:e0184550. doi: 10.1371/journal.pone.0184550.
［21］	McMahon BJ. Implementing evidenced⁃based practice guidelines for the management of chronic hepatitis B virus infection［J］. Am J Med, 2008,121（12 Suppl）:S45⁃S52. doi: 10.1016/j.amjmed. 2008.09.028.
［22］	European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection［J］. J Hepatol, 2017,67（2）:370⁃398. doi: 10.1016/ j.jhep.2017.03.021.
［23］	张浩晔, 刘振国, 张震, 等. 核苷类似物防治乙型肝炎表面抗原阳性的肿瘤患者化疗后乙型肝炎病毒再激活的临床分析［J］. 中华肿瘤杂志, 2010,32（6）:459⁃462. doi: 10.3760/cma.j.issn.0253⁃3766.2010.06.015.
［24］	孔媛媛, 尤红, 贾继东, 等. 世界卫生组织《慢性乙型肝炎病毒感染预防、关怀和治疗指南》制定方法学和核心建议点评［J］. 中华肝脏病杂志, 2015,23（7）:485⁃487. doi: 10.3760/cma.j.issn.1007⁃3418.2015.07.003.

[1]	. Therapeutic effect of combined glucocorticoids on herpes zoster of the head and face in the elderly [J]. Chinese Journal of Dermatology, 2018, 51(9): 670-672.
[2]	Xiao Yuanyuan, Xu Zigang, Xu Zhe, Xiang Xin, Liu Ying, Ma Lin, Yang Zhou. Vincristine combined with glucocorticoids for the treatment of 11 cases of infantile Kasabach-Merritt syndrome [J]. Chinese Journal of Dermatology, 2018, 51(8): 601-603.
[3]	Lu Jinghao, Liu Chaofan, Zhou Xing, Hu Dongyan, Xin Chongmei, Zhu Lubing, Li Ming. Clinical analysis of four cases of dermatomyositis with painful palmar eruptions complicated by fatal rapidly progressive interstitial lung disease [J]. Chinese Journal of Dermatology, 2018, 51(8): 564-568.
[4]	You Wang-Min Qing-wei Geng Xiang WenZhong. Clinical analysis of 38 cases of steroid?induced diabetes mellitus due to glucocorticoid treatment [J]. Chinese Journal of Dermatology, 2018, 51(4): 269-273.
[5]	. Retrospective analysis of 185 inpatients with acute urticaria [J]. Chinese Journal of Dermatology, 2018, 51(3): 224-227.
[6]	TAN Guo-zhen, PENG Hui, MAO Yue-ping, ZENG Fan-qin. Glucocorticoids treatment upregulates the expression of CD62L in CD4⁺CD25⁺T cells in peripheral blood monocytes of patients with systemic lupus erythematosus [J]. Chinese Journal of Dermatology, 2007, 40(6): 362-364.
[7]	WANG Di, CHEN Xi-xue, ZHU Xue jun. Treatment of bullous pemphigoid：a retrospective study with 124 patients over a 20-year period in China [J]. Chinese Journal of Dermatology, 2007, 40(1): 7-9.
[8]	YOU Yi, HAO Fei, DENG Yong-jian. Effects of glucocorticoid therapy on the expression of Caspase-3 and TRAIL receptors in CD4⁺ and CD8⁺T cells of patients with systemic lupus erythematosus [J]. Chinese Journal of Dermatology, 2007, 40(1): 19-21.
[9]	YANG Xue-yuan, HU Zi-jia, BI Zhi-gang, GU Jun, FAN Wei-xin, WANG Se-feng, YU Hao, LOU Dong-hua. Treatment of Eczema and Neurodermatitis with 0.1% Mometasone Furoate Cream: A Multi-Center Clinical Trial [J]. Chinese Journal of Dermatology, 2005, 38(1): 41-43.
[10]	GU Wei-ming, LIAO Ming-min, YANG Yang, WU Lei, HU Wei-zhong. Detection of HSV2-IgG, HBsAg and HCV in Patients with STD and HIV Infection [J]. Chinese Journal of Dermatology, 2004, 37(5): 288-289.
[11]	LI Jie, XIE Hong-fu, SHI Wei, CHEN Ming-liang, CHEN Xiang, DU Qian-jun, CHEN Fu-wen. Effects of Glucocorticoids on Th1/Th2 Cytokine Expression in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus [J]. Chinese Journal of Dermatology, 2004, 37(12): 706-708.
[12]	ZHOU Pingyu, LIAO Kanghuang, XU Ming. Influence of Corticosteroid on Peripheral Blood Lymphocyte in Secondary Syphilis and Prognosis of Syphilis [J]. Chinese Journal of Dermatology, 2001, 34(2): 122-123.
[13]	Wang Zhizhong, Zhen Maorong, Li Huaiyi. Chromosomal Aberrations of Lymphocytes and Keratinocytes in Patients with Psoriasis and the Relationship to HBV [J]. Chinese Journal of Dermatology, 1997, 30(2): 93-95.

Hepatitis B virus reactivation induced by glucocorticoids: an important issue requiring urgent attention in dermatology

PDF

Like

Knowledge

Abstract

Cite this article

share this article

References ［24］

Related Articles 13

Metrics

Comments

Recommended 10